DSM-Firmenich AG (0AC9)
London Exchange · UK · prices in GBP · close of 19 Oct 2026
Key indicators
| Last close | GBP 106.55 |
|---|---|
| 52-week range | 55.30 – 109.75 |
| Return, 1 month / 3 months | +15.0% / +23.2% |
| Return, 1 year / 3 years | +42.8% / +38.3% |
| Trend | Uptrend |
| RSI (14) | 72 |
| Volatility (1 year) | 29.8% |
| Worst drawdown (1 year) | -26.7% |
| Average daily value traded | 20.53M GBP |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
DSM-Firmenich is a Swiss company that supplies ingredients and solutions for nutrition, health and beauty. It makes vitamins, nutritional lipids and other food and feed ingredients, and it produces flavours, fragrances and perfume compounds for food, beverage, household and personal care customers. Its customers include food and beverage makers, animal nutrition companies, cosmetics and household product manufacturers, and pharmaceutical and dietary supplement producers around the world. The company is based in Switzerland and serves industrial and consumer goods markets internationally.
The shares are listed on the London Exchange in UK under the code 0AC9, and the price on this page is in pounds sterling (GBP). Our dividend records, which start in 2019, show payments in 4 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
DSM-Firmenich AG (0AC9) trades on the London Exchange in UK. It last closed at GBP 106.55 on 19 October 2026.
Its price-based Market X-Ray is 80 out of 100 (a strong price profile), ranking 63 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 42.8% and over the last three months it rose 23.2%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 95 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 40.4% | ||
| From 52-week high | -0.8% | ||
| Momentum | 86 · Strong | Rising faster than most stocks on this exchange. | |
| 3-month return | 23.2% | ||
| 6-month return | 62.4% | ||
| 12-month return, skipping the last month | 24.2% | ||
| Stability (higher is calmer) | 59 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 29.8% | ||
| Worst drawdown, 1 year (smaller is calmer) | -26.7% | ||
| Liquidity | 79 · Strong | Trades actively. | |
| Average daily value traded | 20.53M GBP | ||
| Zero-volume days | 0.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 4 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Momentum: Rising faster than most stocks on this exchange.
- Liquidity: Trades actively.
Weak spots
No lens is weak against its exchange.
Returns
| 1 week | +6.7% |
|---|---|
| 1 month | +15.0% |
| 3 months | +23.2% |
| 6 months | +62.4% |
| 1 year | +42.8% |
| 3 years | +38.3% |
| 5 years | – |
Signals
| 50-day / 200-day average | 94.87 / 75.87 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | Yes |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 2.46 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 11 May 2026 | GBX 0.0086 |
| 8 May 2025 | GBX 0.0106 |
| 9 May 2024 | GBX 0.0157 |
| 3 Jul 2023 | GBX 0.0160 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.